Bright Minds Biosciences
DRUG
99 hedge funds and large institutions have $654M invested in Bright Minds Biosciences in 2026 Q2 according to their latest regulatory filings, with 19 funds opening new positions, 47 increasing their positions, 17 reducing their positions, and 12 closing their positions.
176% more repeat investments, than reductions
Existing positions increased: 47 | Existing positions reduced: 17
123% more capital inflows, than outflows
Capital inflows: $205M | Capital outflows: $91.9M
58% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 12
5% more funds holding
Funds holding: 94 → 99 (+5)
1.26% more ownership
Funds ownership: 94.41% → 95.67% (+1.3%)
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
+$25.7M |
| 2 |
Parkman Healthcare Partners
Stamford,
Connecticut
|
+$13M |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$5.22M |
| 4 |
BlackRock
New York
|
+$5.05M |
| 5 |
Trexquant Investment
Stamford,
Connecticut
|
+$4.96M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Perceptive Advisors
New York
|
-$27.5M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
-$12.6M |
| 3 |
Cormorant Asset Management
Boston,
Massachusetts
|
-$12.5M |
| 4 |
Morgan Stanley
New York
|
-$8.96M |
| 5 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$8.67M |
DRUG Hedge Fund Activity: Q2 2026 in Review
99 of the 8,362 institutional investors tracked by Wall St. Rank reported a position in Bright Minds Biosciences (DRUG) for Q2 2026, worth a combined $654M — down 2.5% from $670M a quarter earlier.
Buyers outnumbered sellers: 19 funds opened new DRUG positions and 12 closed out — a net gain of 7 holders — while 47 added to existing stakes and 17 trimmed.
The largest buyer was Point72 Asset Management, opening a new position worth an estimated $25.7M. The largest seller was Perceptive Advisors, exiting entirely with an estimated $27.5M sold.
- 99 institutional investors held Bright Minds Biosciences (DRUG) as of Q2 2026, up from 94 in Q1 2026.
- Funds reported $654M of Bright Minds Biosciences stock for Q2 2026, down 2.5% quarter-over-quarter.
- 19 funds opened new Bright Minds Biosciences positions in Q2 2026 and 12 closed out, a net change of +7 holders.
- The largest Bright Minds Biosciences buyer in Q2 2026 was Point72 Asset Management, an estimated $25.7M added.
- The largest Bright Minds Biosciences seller in Q2 2026 was Perceptive Advisors, an estimated $27.5M sold.
Based on aggregated 13F filings for Q2 2026.